SCHEMBL487212

SCHEMBL487212

C[C@H](OCc1ccccc1)[C@@H](O)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.47
POLB P06746 1/20 0.46
SYK P43405 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
LTA4H P09960 1/20 0.43
CTSS P25774 1/20 0.43
PPARA Q07869 1/20 0.42
SLC1A3 P43003 2/20 0.42
SLC1A2 P43004 2/20 0.42
SLC1A1 P43005 2/20 0.42
MEN1 O00255 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487210 1.00 RCE1 (0.47) RCE1POLBSYKALDH1A1MMP9
SCHEMBL21843005 0.86 ALDH1A1 (0.53) RCE1ALDH1A1MMP9MMP8LTA4H
SCHEMBL21843008 0.86 ALDH1A1 (0.53) RCE1ALDH1A1MMP9MMP8LTA4H
SCHEMBL20400849 0.85 SLC1A3 (0.50) RCE1POLBSYKALDH1A1MMP9
SCHEMBL20400850 0.85 SLC1A3 (0.50) RCE1POLBSYKALDH1A1MMP9
SCHEMBL16672792 0.84 ALDH1A1 (0.47) POLBSYKALDH1A1LTA4HCTSS
SCHEMBL8930328 0.83 LMNA (0.52) RCE1POLBALDH1A1MMP9MMP8
SCHEMBL8930325 0.83 LMNA (0.52) RCE1POLBALDH1A1MMP9MMP8
SCHEMBL8425022 0.83 ALDH1A1 (0.53) POLBSYKALDH1A1LTA4HPPARA
SCHEMBL8425025 0.83 ALDH1A1 (0.53) POLBSYKALDH1A1LTA4HPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362043-B2 Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, 3(R,S)-[2(S)-(3-Benzoylamino-2-oxo-2H-pyridin-1-yl)-3-phenyl-propionylamino]-5-fluoro-4-oxo-pentanoic acid VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-01-29 US disclosed
EP-1833794-B1 3-[2-(3-ACYLAMINO-2-OXO-2H-PYRIDIN-1-YL)-ACETYLAMINO]-4-OXO-PENTANOIC ACID DERIVATIVES AND THEIR USE AS CASPASE INHIBITORS VERTEX PHARMA (US) 2012-02-01 EP disclosed
US-20060160862-A1 Caspase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160862-A1 Caspase inhibitors and uses thereof CASP1, CASP5, CASP3 RCE1 107/4885POLB 3908/4885SYK 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.